tradingkey.logo
tradingkey.logo
Search

Aspire Biopharma Holdings Inc

ASBP
Add to Watchlist
5.610USD
-0.260-4.43%
Close 05/15, 16:00ETQuotes delayed by 15 min
6.79MMarket Cap
LossP/E TTM

Aspire Biopharma Holdings Inc

5.610
-0.260-4.43%

More Details of Aspire Biopharma Holdings Inc Company

Aspire Biopharma Holdings, Inc. is an early-stage biopharmaceutical company. It develops and markets a technology for novel delivery mechanisms for FDA approved drugs, nutraceuticals, and supplements. It has developed and acquired technologies that are a Novel Soluble Formulation which address emergencies and drug efficacy, dosage management, and response time. Its Sublingual Aspirin Product, which addresses cardiology emergencies and pain management, is a granular or powder formulation of a soluble, Ph-neutral, fast-acting aspirin. It also has numerous pharmaceutical and nutraceutical applications under development in various areas, including but not limited to a Viagra/Cialis combination product which is faster acting, requiring decreased dosages with the benefit of a longer half-life, various bi-hormonal drugs such as testosterone, estrogen and weight loss drugs, and thyroid drugs, as well as various supplements including a rapid-absorbing pre-workout and a melatonin sleep aid.

Aspire Biopharma Holdings Inc Info

Ticker SymbolASBP
Company nameAspire Biopharma Holdings Inc
IPO dateFeb 18, 2022
CEO- -
Number of employees- -
Security typeOrdinary Share
Fiscal year-endFeb 18
Address194 Candelaro Drive, #233
CityHUMACAO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryPuerto Rico
Postal code00791
Phone
Website
Ticker SymbolASBP
IPO dateFeb 18, 2022
CEO- -

Company Executives of Aspire Biopharma Holdings Inc

Name
Name/Position
Position
Shareholding
Change
Mr. Kraig Higginson
Mr. Kraig Higginson
Executive Chairman of the Board
Executive Chairman of the Board
8.78K
--
Mr. Howard A. Doss, CPA
Mr. Howard A. Doss, CPA
Director
Director
333.00
--
Mr. Donald G. Fell
Mr. Donald G. Fell
Independent Director
Independent Director
--
--
Mr. Ernest J. Scheidemann, Jr.
Mr. Ernest J. Scheidemann, Jr.
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Barbara J. Sher
Ms. Barbara J. Sher
Director
Director
--
--
DR. Edward Kimball
DR. Edward Kimball
Director
Director
--
--
Mr. Surendra Ajarapu
Mr. Surendra Ajarapu
Director
Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Kraig Higginson
Mr. Kraig Higginson
Executive Chairman of the Board
Executive Chairman of the Board
8.78K
--
Mr. Howard A. Doss, CPA
Mr. Howard A. Doss, CPA
Director
Director
333.00
--
Mr. Donald G. Fell
Mr. Donald G. Fell
Independent Director
Independent Director
--
--
Mr. Ernest J. Scheidemann, Jr.
Mr. Ernest J. Scheidemann, Jr.
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Barbara J. Sher
Ms. Barbara J. Sher
Director
Director
--
--
DR. Edward Kimball
DR. Edward Kimball
Director
Director
--
--

Revenue Breakdown

Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.

Shareholding Stats

Updated: Thu, May 14
Updated: Thu, May 14
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Ardsley Advisory Partners LP
0.74%
Higginson (Kraig)
0.72%
UBS Financial Services, Inc.
0.53%
Friedman (Lance)
0.15%
Ajjarapu (Surendra K)
0.08%
Other
97.78%
Shareholders
Shareholders
Proportion
Ardsley Advisory Partners LP
0.74%
Higginson (Kraig)
0.72%
UBS Financial Services, Inc.
0.53%
Friedman (Lance)
0.15%
Ajjarapu (Surendra K)
0.08%
Other
97.78%
Shareholder Types
Shareholders
Proportion
Individual Investor
1.03%
Hedge Fund
0.76%
Investment Advisor
0.64%
Research Firm
0.06%
Investment Advisor/Hedge Fund
0.02%
Venture Capital
0.02%
Other
97.47%

Institutional Shareholding

Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
66
555.77K
11.06%
+360.57K
2025Q4
63
3.12M
4.40%
--
2025Q3
65
3.12M
11.03%
+825.14K
2025Q2
62
2.05M
9.35%
+603.03K
2025Q1
98
1.44M
45.11%
-19.31M
2024Q4
95
589.74K
302.57%
-13.72K
2024Q3
102
603.46K
307.62%
-79.18K
2024Q2
105
682.64K
311.95%
-1.09M
2024Q1
104
1.77M
266.21%
-22.17M
2023Q4
100
1.85M
266.31%
-691.34K
View more

Shareholder Activity

Name
Shares Held
Proportion
Change
Chg %
Date
Ardsley Advisory Partners LP
268.75K
5.35%
+268.75K
--
Dec 31, 2025
Higginson (Kraig)
263.28K
5.24%
--
--
Feb 17, 2026
UBS Financial Services, Inc.
62.87K
1.25%
+62.68K
+32645.83%
Dec 31, 2025
Friedman (Lance)
55.20K
1.1%
-41.61K
-42.98%
May 06, 2025
Ajjarapu (Surendra K)
28.04K
0.56%
--
--
Dec 01, 2025
Crewe Advisors LLC
20.34K
0.4%
--
--
Dec 31, 2025
Scheidemann (Ernest J. Jr.)
14.11K
0.28%
+1.00
+0.01%
Feb 17, 2026
Doss (Howard A)
10.00K
0.2%
--
--
Feb 17, 2026
XTX Markets LLC
6.64K
0.13%
+5.94K
+853.59%
Dec 31, 2025
View more

Related ETFs

Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
SPAC and New Issue ETF
0%
SPAC and New Issue ETF
Proportion0%

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data

Stock Splits

Date
Ex-dividend Date
Type
Ratio
May 07, 2026
Merger
30→1
Jan 14, 2026
Merger
40→1
Date
Ex-dividend Date
Type
Ratio
May 07, 2026
Merger
30→1
Jan 14, 2026
Merger
40→1
KeyAI